SLN · NASDAQ · STOCK
Silence Therapeutics (SLN) Stock Analysis
$14.60
52W $4.19 – $17.58
49/100
$689.14M
-3.8
1.41
Is SLN Bullish or Bearish?
Mixed.
Innellis AI committee rates Silence Therapeutics plc (SLN) Watch with a composite score of 49/100
, based on 6 analysts with 50% agreement.
Last updated September 06, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +10.62 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -9.38 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Growth Analyst remains cautious — revenue declining -98.6% yoy -- this is not a growth story right now. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- ROE of only -103.3% -- cheap may mean cheap for a reason — Value
- Debt-to-equity of 2.02 adds balance-sheet risk to the value case — Value
- Revenue declining -98.6% YoY -- this is not a growth story right now — Growth
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 79 -- overbought on the larger timeframe too — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of September 06, 2026
Overall Committee Score
49/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 99%
of 192 Healthcare peers
Value Analyst
bearish
40
/ 100 · Moderate confidence
Multiples don't clear a genuine value bar here, or cheapness looks justified by weak fundamentals
− ROE of only -103.3% -- cheap may mean cheap for a reason
Growth Analyst
bearish
25
/ 100 · Moderate confidence
Growth story is weak, decelerating, or inconsistent
− Revenue declining -98.6% YoY -- this is not a growth story right now
Technical Analyst
bullish
61
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
− MACD histogram negative -- bearish momentum
Risk Analyst
bearish
32
/ 100 · Moderate confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− High leverage (debt-to-equity 2.02) amplifies downside in a stress scenario
Macro Analyst
bullish
80
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst
neutral
58
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager
neutral
45
/ 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2704.43)
Investment Thesis Evolution
Committee score moved marginally from 49.4 to 49.4.
Comparing 2026-09-05 to 2026-09-06 (1 day apart).
Technical Analysis
RSI (14)
66.6
Neutral
MACD Histogram
-0.004
Bearish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Hh Hl
Bollinger %B
0.73
Inside Bands
Price vs Moving Averages
EMA 9
$14.21
Above
EMA 21
$13.58
Above
EMA 50
$12.07
Above
EMA 200
$8.58
Above
Fundamental Analysis
Valuation
77
Growth
50
Profitability
19
Financial Health
100
Cash Flow
15
Valuation
P/E Ratio
-3.8×
P/B Ratio
5.97×
PEG Ratio
-0.28
Dividend Yield
0.00%
52W High
$17.58
52W Low
$4.19
Quality & Growth
ROE
-14222.5%
ROA
-6741.5%
Gross Margin
5100.1%
Operating Margin
—
Revenue Growth YoY
—
Debt / Equity
0.00
AI Fundamental Assessment
P/E ratio of -3.8 (inexpensive relative to a 15-40x range); Price-to-book of 6.0x; PEG ratio of -0.3 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -142.2%; Return on assets of -67.4%; Net margin of -9759.2%; Gross margin of 51.0%; Current ratio of 7.42 (healthy short-term liquidity); Debt-to-equity of 0.00; Free cash flow per share is negative (-2.69); EPS growth decelerating (+158.0% -> -222.0% QoQ); Average YoY EPS growth of 158.0%
Get the Full SLN Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →